Acquisition

After explosive growth under private equity, hunting apparel giant KUIU is sold to a new conservation-minded ownership group. What's next for the brand?

Arkansas-based Home BancShares is buying its way into Tennessee's booming economy. We dissect the 'triple accretive' deal to acquire Mountain Commerce.

A new partnership aims to advance a novel antibody for FTLD, a devastating dementia, showcasing a powerful model for biotech innovation and strategic growth.

John Crowley, who fought to save his own children, will now shape the future of medicine as he headlines the landmark 2026 MDA conference.

A routine filing from wealth manager Rathbones reveals its 7.01% stake in Idox Plc, putting a spotlight on the software firm's acquisition and its future.

In a stunning strategic shift, Transcontinental sells its largest division to ProAmpac, rewarding shareholders and refocusing on its printing roots.

A deepening corporate governance battle pits STAAR Surgical's board against its largest shareholder and all major proxy firms over a $1.5B Alcon deal.

Onex cashes out of Ryan Specialty with a stunning 49% IRR. We dive into the strategy behind the $1.2B exit and what it signals for specialty insurance.

As CEO J.K. Symancyk prepares for a key investor conference, Signet Jewelers' new strategy faces the test of a market transformed by tech and ethics.

A top care provider changes hands not by choice, but by debt. What does Colisée's fate reveal about the risks of private equity in social care?

ATI Inc. names operational veteran Rob Foster as its new CFO, signaling a strategic bet that manufacturing prowess is the key to financial success.

For 14 straight years, Hamilton Lane has been a 'Best Place to Work.' We analyze why this cultural consistency is its most potent strategic asset.

A new 31-strain vaccine enters final trials, threatening to upend the market and offer unprecedented protection against a persistent bacterial threat.

Antero Resources executes a complex asset swap, doubling down on the Marcellus Shale. We break down the financial engineering behind the multi-billion dollar deal.

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.

With a fresh $62M in funding, WELLSTAR is accelerating its AI and acquisition strategy ahead of a planned 2026 spinout, aiming to rewire Canadian healthcare.

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.

Beyond the $1.2B price tag, Infinity's deal reveals a masterclass in energy M&A, strategic partnerships, and the consolidation of America's shale plays.

For 12 years, one firm has dominated workplace awards. We explore how its employee-owned model creates an unbeatable cultural advantage in finance.

The new SANY-Pony.ai autonomous truck is production-ready for 2026, promising to slash freight costs, boost profits, and redefine logistics.